Company Information

  

Address: 167 SIDNEY STREET  
City: CAMBRIDGE 
State: MA 
Zip Code: 02139 
Telephone: 617-679-5500 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. We use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: our Toll-like receptor, or TLR, targeting technology and our third-generation antisense, or 3GA, technology. We developed these platforms based on our scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using our TLR targeting technology, we design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. Using our 3GA technology, we are developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. We believe that our 3GA technology may potentially reduce the immunotoxicity and increase the potency of earlier generation antisense and RNA interference, or RNAi, technologies.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-0.32NAN/E
06/2017-0.32NAN/E
03/2017-0.29NAN/E
12/2016-0.30NAN/E
09/2016-0.42NAN/E
06/2016-0.41NAN/E
03/2016-0.41NAN/E
12/2015-0.42NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.06Total Liab/Total Assets0.09
Net Inc/Total Assets-0.34Total Liab/Inv Cap0.10
Net Inc/Inv Cap-0.37Total Liab/Comm Equity0.02
Pretax Inc/Net Sales-2.37Interest Coverage Ratio-478.86
Net Inc/Net Sales-2.37Curr Debt/Equity0.00
Cash Flow/Net Sales-1.74LTD/Equity0.00
SG&A/NetSales0.93Total Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio11.87
Inventory TurnoverNACurrent Ratio11.87
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.16Inv/Curr AssetsNA
Net Sales/PP&E8.74  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.16 0.19 0.38 15.28
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.92 3.89 4.08 3.53
Operating Income -14.67 -21.59 -15.19 0.74
Interest Exp 0.01 0.01 0.02 0.02
Pretax Income -14.53 -21.47 -15.06 0.82
Other Income 0.15 0.13 0.15 0.10
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -14.53 -21.47 -15.06 0.82

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 65.34 77.24 91.26 109.01
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 69.01 81.44 95.50 111.04
Net Property, Plant & Equipment 1.41 1.60 1.74 1.85
Total Assets 70.75 83.37 97.57 113.23
Liabilities        
Accounts Payable 6.97 6.48 5.72 7.95
Debt in Current Liabilities 0.29 0.31 0.30 0.29
Total Current Liabilities 7.82 7.35 7.01 9.35
Long-Term Debt 0.00 0.05 0.13 0.21
Total Liabilities 8.67 8.50 7.38 9.88
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.15 0.15 0.15 0.15
Retained Earnings -589.57 -575.04 -553.57 -538.47
Treasury Stock NA NA NA NA
Total Stockholders' Equity 62.08 74.87 90.19 103.35
Total Liabilities and Stockholders' Equity 70.75 83.37 97.57 113.23

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -11.88 -14.23 -17.65 4.75
Net Cash Provided by Investing Activities 1.18 8.91 16.69 2.76
Net Cash Provided by Financing Activities -0.01 0.29 -0.02 51.01

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.05-19.24-0.81
12/20130.05-18.23-0.48
12/20140.07-38.64-0.47
12/20150.25-48.56-0.42
12/201616.20-38.39-0.30
Growth Rates322.16----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/179047,36924.31




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.